Oculis (OCS) Expected to Announce Quarterly Earnings on Thursday

Oculis (NASDAQ:OCS) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $0.2340 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Stock Performance

NASDAQ OCS opened at $11.99 on Wednesday. Oculis has a 1-year low of $10.52 and a 1-year high of $34.47. The company has a market capitalization of $695.18 million, a P/E ratio of -5.63 and a beta of 0.51. The business has a 50 day moving average price of $13.07 and a 200 day moving average price of $22.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18.

Wall Street Analyst Weigh In

Several research firms have weighed in on OCS. Stifel Nicolaus lowered their target price on Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Oculis in a research note on Thursday, June 11th. Guggenheim dropped their target price on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of Oculis from a “sell” rating to a “strong sell” rating in a report on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.33.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OCS. Millennium Management LLC purchased a new stake in shares of Oculis during the fourth quarter worth about $312,000. Marshall Wace LLP purchased a new position in shares of Oculis during the second quarter valued at approximately $393,000. Renaissance Technologies LLC purchased a new position in shares of Oculis during the fourth quarter valued at approximately $499,000. Geode Capital Management LLC boosted its position in Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.